← Browse by Condition
Medical Condition
diffuse large b cell lymphoma not otherwise specified
Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2
NCT04231877 Phase 1
Recruiting
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Enrollment
56 pts
Location
United States
Sponsor
University of Washington
NCT06014762 Phase 1
Recruiting
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Enrollment
120 pts
Location
United States
Sponsor
Poseida Therapeutics, Inc.
NCT07097363 Phase 2
Recruiting
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Enrollment
18 pts
Location
United States
Sponsor
University of Washington
NCT05908409 Phase 1, Phase 2
Recruiting
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Enrollment
37 pts
Location
Spain
Sponsor
IDP Discovery Pharma S.L.